PIK3CA and breast cancer: In 2015, Bosch et al. [106] identified an enhanced luminal gene expression signature controlling ER transcription in ER+, PIK3CA-mutation bearing breast cancer cells following treatment with therapeutic doses of PI3K or AKT inhibitors.